<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122745">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01975272</url>
  </required_header>
  <id_info>
    <org_study_id>METC 12-2-018</org_study_id>
    <nct_id>NCT01975272</nct_id>
  </id_info>
  <brief_title>The Use of Iron Therapy for Patients With Anemia After Surgery</brief_title>
  <acronym>VITAPOP</acronym>
  <official_title>The Value of Iron Treatment for Postoperative Patients With Anemia: a Randomized Double Blind Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vifor Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether oral or intravenous iron is effective in
      the treatment of anaemia (iron-poor blood) after gynaecologic surgery.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>3 weeks postoperative</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>1,3 and 6 weeks postoperative</time_frame>
    <safety_issue>No</safety_issue>
    <description>Quality of life will be determined by using the next questionnaires: European Health Related Quality of Life  (euro HRQol) and Multidimensional Fatigue Inventory (MFI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects of medication</measure>
    <time_frame>1,3 and 6 weeks postoperative</time_frame>
    <safety_issue>No</safety_issue>
    <description>In the questionnaire one has to fill out if there are any side effects like Nausea; Stomach ache; constipation; Diarrhea; Skin rash; Headache; Dizziness; Other....</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive value of other parameters C reactive protein (CRP) ,transferrin, ferritin, hepcidin</measure>
    <time_frame>3 and 6 weeks postoperative</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Postoperative Anaemia</condition>
  <arm_group>
    <arm_group_label>Ferinject</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once an infusion of Ferinject 1000 mg, 1 day after surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ferrous fumarate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 times  a day 200 mg ferrous fumarate, starting 24-48 hours after surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo infusion and tablets</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patient will get a once a placebo infusion (250 ml NaCl), one day after surgery, and 60 placebo tablets for 30 days (2 tablets a day), starting 24-48 hours after surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferinject</intervention_name>
    <arm_group_label>Ferinject</arm_group_label>
    <other_name>intravenous iron</other_name>
    <other_name>ferric carboxymaltose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferrous fumarate</intervention_name>
    <arm_group_label>Ferrous fumarate</arm_group_label>
    <other_name>Oral iron</other_name>
    <other_name>Iron (II) fumarate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for ferrous fumarate</intervention_name>
    <arm_group_label>Ferinject</arm_group_label>
    <arm_group_label>Placebo infusion and tablets</arm_group_label>
    <other_name>Placebo tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for ferinject</intervention_name>
    <arm_group_label>Ferrous fumarate</arm_group_label>
    <arm_group_label>Placebo infusion and tablets</arm_group_label>
    <other_name>NaCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gynecological surgery

          -  Hb 5-7 mmol/L

        Exclusion Criteria:

          -  Pregnancy

          -  Oncological operations

          -  Infections (PID)

          -  Diagnostic procedures: level 1 laparoscopies (diagnostic, sterilization,  tubal
             testing; Hysteroscopies

          -  Smaller therapeutic procedures: large loop excision of transformation zone  (LLETZ),
             Conization,

          -  Small vulvar / vaginal operations such as (cysts,  labia correction)

          -  Endometrial ablation

          -  Legal incapacity

          -  The patient has used pre-operatively an iron preparation and / or blood transfusion
             or during the surgery

          -  Hematologic disorders

          -  Erythropoiesis-stimulating agents &amp;lt; 3months ago

          -  Myelosuppressive therapy in history

          -  Hepatitis

          -  HIV

          -  Alcohol abuses

          -  Not understanding Dutch

          -  Allergic reaction to iron therapy in past
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Celine CMJG Lardenoije, Drs.</last_name>
    <phone>00316-17028468</phone>
    <email>c.lardenoije@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roy RFPM Kruitwagen, Prof. Dr.</last_name>
    <phone>0031-433874764</phone>
    <email>r.kruitwagen@mumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maastricht University Medical Centre</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Roy RFPM Kruitwagen, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orbis Medical Centre</name>
      <address>
        <city>Sittard</city>
        <state>Limburg</state>
        <zip>6162 BG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Celine CMJG Lardenoije, Drs.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 28, 2013</lastchanged_date>
  <firstreceived_date>September 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>postoperative</keyword>
  <keyword>anemia</keyword>
  <keyword>gynaecologic</keyword>
  <keyword>surgery</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ferrous fumarate</mesh_term>
    <mesh_term>Iron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
